Agency Header

Drug Utilization Review Board

The Drug Utilization Review (DUR) Board is responsible for the establishment of standards and criteria for the prospective and retrospective DUR programs. The DUR Board is charged with making recommendations for educational interventions to prescribers and pharmacists to identify and reduce overuse, abuse, fraud, and inappropriate or medically unnecessary care. Health Information Designs, LLC (HID) assists the pharmacy program in conducting population-based educational interventions, approved by the DUR Board, for both medical prescribers and pharmacy providers.

Drugs or drug classes which are reviewed and found to be inappropriately utilized or have significant safety concerns are deemed candidates for prior authorization. These reviews are considered by the DUR Board and appropriate criteria for approval are determined by them, with input from medical and pharmacy providers, drug manufactures, and other experts


Members
Lester Labus, MD, Chairman                   Ernest Miller DO 
Kc Lovin, PA-C, Vice-Chair  Mary Nemeth Pyles, MSN, RN, CS
C.K. Babcock, PharmD  Patrick Regan, PharmD
Scott Brown, RPh  Christopher Terpening, PharmD, PhD
Myra Chiang, MD          John Vanin, MD 
Christopher Booth, PharmD  

Follow us on Facebook